| dc.contributor |
Universitat de Vic - Universitat Central de Catalunya. Càtedra de la Sida i Malalties Relacionades |
| dc.contributor.author |
Andreu-Crespo, A. |
| dc.contributor.author |
Llibre, Josep M. |
| dc.contributor.author |
Cardona-Peitx, G. |
| dc.contributor.author |
Sala-Piñol, F. |
| dc.contributor.author |
Clotet, Bonaventura |
| dc.contributor.author |
Bonafont-Pujol, X. |
| dc.date |
2015 |
| dc.identifier |
Andreu-Crespo, À., Llibre, J. M., Cardona-Peitx, G., Sala-Piñol, F., Clotet, B., & Bonafont-Pujol, X. (2015). Hidden costs of antiretroviral treatment: The public health efficiency of drug packaging. Drug Design, Development and Therapy, 9, 4287-4290. |
| dc.identifier |
1177-8881 |
| dc.identifier |
http://hdl.handle.net/10854/4271 |
| dc.identifier |
https://doi.org/10.2147/DDDT.S87075 |
| dc.identifier.uri |
http://hdl.handle.net/10854/4271 |
| dc.description |
While the overall percentage of unused antiretroviral medicines returned to the hospital pharmacy is low, their cost is quite high. Adverse events, treatment failure, pharmacokinetic interactions, pregnancy, or treatment simplification are common reasons for unplanned treatment changes. Socially inefficient antiretroviral packages prevent the reuse of drugs returned to the hospital pharmacy. We defined antiretroviral package categories based on the excellence of drug packaging and analyzed the number of pills and costs of drugs returned during a period of 1 year in a hospital-based HIV unit attending to 2,413 treated individuals. A total of 6,090 pills (34% of all returned antiretrovirals) - with a cost of 47,139.91 € - would be totally lost, mainly due to being packed up in the lowest efficiency packages. Newer treatments are packaged in low-excellence categories of packages, thus favoring the maintenance of these hidden costs in the near future. Therefore, costs of this low-efficiency drug packaging, where medication packages are started but not completed, in high-cost medications are substantial and should be properly addressed. Any improvement in the packaging by the manufacturer, and favoring the choice of drugs supplied through efficient packages (when efficacy, toxicity, and convenience are similar), should minimize the treatment expenditures paid by national health budgets. |
| dc.format |
application/pdf |
| dc.language |
eng |
| dc.publisher |
Dove Medical Press |
| dc.rights |
Aquest document està subjecte a aquesta llicència Creative Commons |
| dc.rights |
http://creativecommons.org/licenses/by/3.0/es/ |
| dc.rights |
info:eu-repo/semantics/openAccess |
| dc.subject |
Sida -- Tractament |
| dc.title |
Hidden costs of antiretroviral treatment: the public health efficiency of drug packaging |
| dc.type |
info:eu-repo/semantics/article |
| dc.type |
info:eu-repo/publishedVersion |
